Novo Nordisk Back to the Office Amidst Job Cuts

Wegovy maker Novo Nordisk mandates a full return to the office for all employees amid job cuts and a $450 billion stock plunge, aiming to boost collaboration and decision-making as competition in the obesity drug market intensifies, sparking debate over work-life balance and echoing a growing trend among major employers to end remote work. Hosted on Acast. See acast.com/privacy for more information.